GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Erasca Inc (NAS:ERAS) » Definitions » Asset Turnover

Erasca (Erasca) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Erasca Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Erasca's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Erasca's Total Assets for the quarter that ended in Mar. 2024 was $382.66 Mil. Therefore, Erasca's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Erasca's annualized ROE % for the quarter that ended in Mar. 2024 was -46.30%. It is also linked to ROA % through Du Pont Formula. Erasca's annualized ROA % for the quarter that ended in Mar. 2024 was -36.60%.


Erasca Asset Turnover Historical Data

The historical data trend for Erasca's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Erasca Asset Turnover Chart

Erasca Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - - - -

Erasca Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Erasca's Asset Turnover

For the Biotechnology subindustry, Erasca's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Erasca's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Erasca's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Erasca's Asset Turnover falls into.



Erasca Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Erasca's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (514.909+395.297)/ 2 )
=0/455.103
=0.00

Erasca's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (395.297+370.022)/ 2 )
=0/382.6595
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Erasca  (NAS:ERAS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Erasca's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-140.068/302.5475
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-140.068 / 0)*(0 / 382.6595)*(382.6595/ 302.5475)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.2648
=ROA %*Equity Multiplier
=-36.60 %*1.2648
=-46.30 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Erasca's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-140.068/382.6595
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-140.068 / 0)*(0 / 382.6595)
=Net Margin %*Asset Turnover
= %*0
=-36.60 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Erasca Asset Turnover Related Terms

Thank you for viewing the detailed overview of Erasca's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Erasca (Erasca) Business Description

Traded in Other Exchanges
N/A
Address
3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Executives
Jonathan E Lim director, 10 percent owner, officer: See Remarks 11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Start Valerie Denise Harding director C/O IGNYTA, INC., 11111 FLINTKOTE AVE., SAN DIEGO CA 92121
Alexander W. Casdin director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Shannon Morris officer: Chief Medical Officer C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO CA 92121
James Arthur Bristol director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Cormorant Asset Management, Lp director 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen director C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp director 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp director 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Jean I Liu director 21823 30TH DRIVE SE, BOTHELL WA 98021
Pratik S Multani director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Julie Hambleton director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Ebun Garner officer: General Counsel C/O ALPHATEC HOLDINGS, INC., 2051 PALOMAR AIRPORT ROAD, CARLSBAD CA 92011
Lim Conyee T. 10 percent owner C/O ERASCA, INC., 10835 ROAD TO THE CURE #140, SAN DIEGO CA 92121
Arch Venture Fund X, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Erasca (Erasca) Headlines